Drugs Acting on the Neuromuscular Junction Flashcards

(38 cards)

1
Q

List the 3 ways of blocking neuromuscular transmission.

A
  • Presynaptically, by inhibiting ACh synthesis.
    • Rate limiting step is choline uptake - blocking of the choline transporter stops it from being taken up by the cell.
  • Presynaptically, by inhibiting ACh release.
  • Postsynaptically, by interfering with the actions of ACh on the receptor.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

List substances which can inhibit ACh release.

A
  • Local anaesthetics
  • General inhalational anaesthetics
  • Inhibitors / competitors of calcium
    • Magnesium ions
    • Some antibiotics
      • Aminoglycosides (e.g. gentamicin)
      • Tetracycline
  • Neurotoxins
    • Botulinum toxin
    • β-bungarotoxin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

How do local anaesthetics work to inhibit ACh release?

A

They block voltage-gated sodium channels.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are the clinical uses of neuromuscular blocking agents?

A
  • Endotracheal intubation
  • During surgical procedures
    • To allow surgical access to abdominal cavity.
    • To ensure immobility
      • E.g. to prevent cough during head and neck surgery.
    • Allow relaxation to reduce displaced fracture dislocation.
    • To decrease the concentration of general anaesthetic needed.
  • Infrequently in intensive care
    • Mechanical ventilation at extremes of hypoxia
  • During ECT
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Give examples of nicotinic ACh receptor agonists.

A
  • Nicotine
  • Suxamethonium - depolarising blocker of the NMJ.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Give examples of nicotinic ACh receptor antagonists.

A
  • Tubocurarine
  • Atracurium - non-depolarising blocker of the NMJ. It does not cause a conformational change.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Describe the action of non-depolarising blockers (competative antagonists of nicotinic ACh receptors at the NMJ).

For example: tubocurarine or atracurium.

A
  • Prevents ACh binding to receptor by occupying site.
  • Decreases the motor end plate potential (EPP).
  • Decreases depolarisation of the motor end plate region.
  • No activation of the muscle action potential.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Describe the action of depolarising blockers (agonists of nicotinic ACh receptors at the NMJ).

For example: suxamethonium.

A
  • Persistent depolarisation of the motor end plate.
  • Prolonged EPP.
  • Prolonged depolarisation of the muscle membrane.
  • Membrane potential above the threshold for the resetting of the voltage-gated sodium channels.
  • Sodium channels remain refractory.
  • No more muscle action potentials are generated.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What are the two phases of a depolarising block?

A
  • Phase 1
    • Muscle fasciculations observed, then blocked.
    • Repolarisation inhibited
      • K+ leaks from cells (hyperkalemia)
    • Voltage-gated Na+ channels are kept inactivated
  • Phase 2
    • Prolonged / increased exposure to drug
    • ‘Desensitisation blockade’
      • Depolarisation cannot occur, even in the absence of the drug.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Give 3 examples of aminosteroidal non-depolarising neuromuscular blockers.

A
  • Pancuronium
  • Vecuronium
  • Rocuronium
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Give 2 examples of benzylisoquiolinium non-depolarising neuromuscular blockers.

A
  • Atracurium
  • Mivacurium
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is the primary depolarising neuromuscular blocker?

A

Suxamethonium

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What are the properties of pancuronium?

A
  • Onset - medium
  • Duration - long
  • Side effects - tachycardia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are the properties of vecuronium?

A
  • Onset - medium
  • Duration - medium
  • Few side effects
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What are the properties of rocuronium?

A
  • Onset - fast
  • Duration - medium
  • Side effects - tachycardia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are the properties of atracurium?

A
  • Onset - medium
  • Duration - medium
  • Side effects - hypotension / bronchospasm
    • (Histamine release)
17
Q

What are the properties of mivacurium?

A
  • Onset - fast
  • Duration - short
  • Side effects - hypotension / bronchospasm
    • (Histamine release)
18
Q

What are the properties of suxamethonium?

A
  • Onset - fast
  • Duration - short
  • Side effects:
    • Bradycardia (muscarinic agonist effect)
    • Cardiac dysrhythmias (increased plasma K+ concentration)
    • Raised intraocular pressure (nicotinic agonist effect)
    • Postoperative myalgia (muscle fasciculations)
    • Malignant hyperthermia (ryanodine receptor related)
19
Q

Which neuromuscular blockers are metabolised and eliminated by ester hydrolysis and Hofmann elimination?

20
Q

Which neuromuscular blockers are metabolised and eliminated by plasma cholinesterases?

A
  • Mivacurium
  • Suxamethonium

NB - Plasma cholinesterase defficiency means that it is not so able to break down suxamethonium causing a very long prolonged block.

21
Q

Which neuromuscular blockers are metabolised and eliminated by hepatic metabolism?

A
  • Pancuronium
  • Vecuronium
22
Q

Which neuromuscular blocker is unchanged in bile / urine?

23
Q

What regulates the duration of the action of ACh?

24
Q

Describe the properties of acetylcholinesterase (ACh.E).

A
  • True cholinesterase, specific for hydrolysis of ACh.
  • Present in conducting tissue and RBCs.
  • Bound to basement membrane in the synaptic cleft.

NB - acetylcholinesterase can be used in myesthenia gravis (autoimmune disease) which (basically) blocks ACh. So anticholinesterases prevent the degradation of ACh so can restore transmission.

25
Describe the properties of plasma cholinesterase.
* Pseudocholinesterase, broad spectrum of substrates * Widespread distribution * Soluble in plasma
26
What are the properties of anticholinesterase drugs?
* Are all inhibitors of cholinesterase enzymes * Therefore, there is an increased availability of ACh at the NMJ by decreased degradation. * Increases duration of activity of ACh at NMJ. * More ACh to compete with non-depolarising blockers.
27
Give 2 examples of anticholinesterase drugs which are quaternary amines.
* Neostigmine * Pyridostigmine
28
Give 2 examples of anticholinesterase drugs which are organophosphates.
* Dyflos * Parathion
29
What are the properties of neostigmine?
* Duration - medium * Mechanism of action - formation of carbamylated enzyme complex.
30
What are the properties of pyridostigmine?
* Duration - medium * Mechanism of action - formation of carbamylated enzyme complex
31
What are the properties of dyflos?
* Duration - long * Mechanism of action - irreversible inhibition
32
What are the properties of parathion?
* Duration - long * Mechanism of action - irreversible inhibition
33
What is the effect of carbamylation?
Slow the rate of hydrolysis
34
Describe phosphorylation by dyflos / parathion.
* Phosphorylation by dyflos / parathion is highly stable * Recovery depends on synthesis of new enzyme * Can be coaxed off by pralidoxime
35
What are the effects of anticholinesterases on the CNS?
* Initial excitation with convulsions * Unconsciousness and respiratory failure
36
What are the effects of anticholinesterases on the autonomic nervous system?
* **S**alivation * **L**acrimation * **U**rination * **D**efacation * **G**astrointestinal upset * **E**mesis * Bradycardia * Hypotension * Bronchoconstriction * Pupillary constriction
37
What are the clinical uses of anticholinesterases?
* **In anaesthesia** * **​**Reverse non-depolarising muscle blockade * Given with atropine or glycopyrrolate to counteract parasympathetic effects * **Myasthenia gravis** * **​**Increase neuromuscular transmission * **Glaucoma** * **​**Decrease intraoccular pressure * **Alzheimer's disease** * **​**Enhance the cholinergic transmission in the CNS
38
What is sugammadex?
* **Selective relaxant binding agent (SRBA)** * Reverses the effects of rocuronium and vecuronium